Achillion Pharma (ACHN) Announces Presentation of Odalasvir, AL-335 and Simeprevir Phase 2b Data
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) announced that interim results from an ongoing phase 2a clinical trial, being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to evaluate all-oral combination regimens, containing odalasvir, AL-335 and simeprevir, were accepted for presentation at the EASL – American Association for the Study of Liver Diseases (AASLD) Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap for Cure, being hosted in Paris, France on September 23 – 24, 2016.
The eposter, entitled “Short duration treatment with AL-335 and odalasvir (ODV), with or without simeprevir (SMV), in treatment naïve patients with hepatitis C virus (HCV) genotype (GT) 1 infection,” will be presented on Friday, September 23, 2016.
This phase 2a study aims to establish the safety, pharmacokinetics and efficacy of doublet and triplet regimens, consisting of odalasvir and AL-335 with or without simeprevir, in treatment naïve patients with genotype 1 HCV infection for treatment durations of eight weeks or less. Further information about this study can be found at www.clinicaltrials.gov. Study identifier: NCT02569710.
The hepatitis C virus (HCV) is one of the most common causes of viral hepatitis, which is an inflammation of the liver. It is currently estimated that more than 150 million people are infected with HCV worldwide including approximately 5 million people in the United States. Three-quarters of the HCV patient population is undiagnosed; it is a silent epidemic and a major global health threat. Chronic hepatitis, if left untreated, can lead to permanent liver damage that can result in the development of liver cancer, liver failure or death. Despite available treatments, there remains a significant unmet need for many patients infected with HCV.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB), AbbVie (ABBV) Receive Health Canada Approve for Once-Monthly Zinbryata
- Emergent BioSolutions (EBS) Signs $911M CDC Follow-On Contract for Anthrax Vaccine
- Akili, Pfizer (PFE) Report Positive Data from Study to Detect Subtle Cognitive Changes in Healthy Subjects at Risk of Developing AD
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!